The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-1801
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer ; volume:4 ; number:1 ; day:30 ; month:1 ; year:2015 ; pages:1-10 ; date:12.2015
SpringerPlus ; 4, Heft 1 (30.1.2015), 1-10, 12.2015
- Creator
-
Thaker, Nikhil G.
Hoffman, Karen E.
Stauder, Michael C.
Shaitelman, Simona F.
Strom, Eric A.
Tereffe, Welela
Smith, Benjamin D.
Perkins, George H.
Huo, Lei
Munsell, Mark F.
Pusztai, Lajos
Buchholz, Thomas A.
Woodward, Wendy A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40064-015-0840-y
- URN
-
urn:nbn:de:101:1-2021082806221364821611
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Thaker, Nikhil G.
- Hoffman, Karen E.
- Stauder, Michael C.
- Shaitelman, Simona F.
- Strom, Eric A.
- Tereffe, Welela
- Smith, Benjamin D.
- Perkins, George H.
- Huo, Lei
- Munsell, Mark F.
- Pusztai, Lajos
- Buchholz, Thomas A.
- Woodward, Wendy A.
- SpringerLink (Online service)
Other Objects (12)
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Swinging Complements
Predicate complements
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
A strain-guided trial of cardioprotection in early-stage breast cancer patients on anti-HER2 therapy (PROTECT HER2)
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
Robot-assisted fluorescent sentinel lymph node identification in early-stage colon cancer
Can Axillary Lymph Node Dissection Be Safely Omitted for Early-Stage Breast Cancer Patients with Sentinel Lymph Node Micrometastasis?
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Swinging Complements
Predicate complements
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
A strain-guided trial of cardioprotection in early-stage breast cancer patients on anti-HER2 therapy (PROTECT HER2)
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
Robot-assisted fluorescent sentinel lymph node identification in early-stage colon cancer
Can Axillary Lymph Node Dissection Be Safely Omitted for Early-Stage Breast Cancer Patients with Sentinel Lymph Node Micrometastasis?
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Swinging Complements
Predicate complements
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
A strain-guided trial of cardioprotection in early-stage breast cancer patients on anti-HER2 therapy (PROTECT HER2)
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
Robot-assisted fluorescent sentinel lymph node identification in early-stage colon cancer